Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: A liew

Endocrine Practice

Volumn 19, Issue 5, 2013, Pages 821-828

  Aranha, Algenes Alphius ^a   Amer, Saima ^a   Reda, Elham Saleh ^a,b   Broadley, Simon A ^a,b   Davoren, Peter M ^a,b  

^a GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CARBIMAZOLE; INTERFERON BETA SERINE; METHYLPREDNISOLONE; PROPRANOLOL; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADULT; AUTOIMMUNE THYROIDITIS; CASE REPORT; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; EUTHYROIDISM; EYE SWELLING; FEMALE; GOITER; GRAVES DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCREASED APPETITE; LABILE MOOD; LETHARGY; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; REVIEW; SIDE EFFECT; SUBTOTAL THYROIDECTOMY; SWEATING; THYROID FUNCTION TEST; THYROTOXICOSIS; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; THYROID DISEASES;

EID: 84886881340     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13020.RA     Document Type: Review

References (49)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372:1502-1517.
2. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2001;3:137-143.
3. Xia MQ, Tone M, Packman L, Hale G, Waldmann H. Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol. 1991;21: 1677-1684.
4. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15:1567-1574.
5. Slavin S, Or R, Weiss L, et al. Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1. Adv Exp Med Biol. 1985; 186:813-818.
6. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet. 2012;380:1819-1828.
7. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet. 2012;380:1829-1839.
8. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves? orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273-285.
9. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46:296-304.
10. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New Engl J Med. 2008;359:1786-1801.
11. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78:1069-1078.
12. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354:1691-1695.
13. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77:573-579.
14. Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol. 2012;19:307-311.
15. Rotondi M, Oliviero A, Profice P, et al. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol Invest. 1998;21:748-752.
16. Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother. 2012;12:335-341.
17. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis. 2008;67:1322-1327.
18. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: Implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. 2003;101:1422-1429.
19. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128:260-270.
20. Fabian I, Flidel O, Gadish M, Kletter Y, Slavin S, Nagler A. Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils. Exp Hematol. 1993;21:1522-1527.
21. Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23: 693-702.
22. Hsiao LT, Liu JH, Yen CC, et al. Relapse of Graves? disease after successful allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;28:1151-1153.
23. Gilquin J, Viard JP, Jubault V, Sert C, Kazatchkine MD. Delayed occurrence of Graves? disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet. 1998;352:1907-1908.
24. Tchao NK, Turka LA. Lymphodepletion and homeostatic proliferation: Implications for transplantation. Am J Transplant. 2012;12:1079-1090.
25. Penhale WJ, Farmer A, Irvine WJ. Thyroiditis in T cell-depleted rats. Influence of strain, radiation dose, adjuvants and antilymphocyte serum. Clin Exp Immunol. 1975;21: 362-375.
26. Petek-Balci B, Yayla V, Ozer F. Multiple sclerosis and Hashimoto thyroiditis: Two cases. Neurologist. 2005;11: 301-304.
27. Watanabe M, Amino N, Hochito K, Watanabe K, Kuma K, Iwatani Y. Opposite changes in serum soluble CD8 in patients at the active stages of Graves? and Hashimoto's diseases. Thyroid. 1997;7:743-747.
28. Fowell D, Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med. 1993;177:627-636.
29. Uchimura K, Itoh M, Yamamoto K, et al. The effects of CD40- and interleukin (IL-4)-activated CD23+ cells on the production of IL-10 by mononuclear cells in Graves? disease: The role of CD8+ cells. Clin Exp Immunol. 2002;128: 308-312.
30. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain. 2000; 123:1102-1111.
31. Henderson RD, Bain CJ, Pender MP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci. 2000;7:434-437.
32. Sloka JS, Phillips PW, Stefanelli M, Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J Autoimmune Dis. 2005;2:9.
33. O?Gorman C, Lin R, Stankovich J, Broadley SA. Modelling genetic susceptibility to multiple sclerosis with family data. Neuroepidemiology. 2013;40:1-12.
34. Hillert J. Human leukocyte antigen studies in multiple sclerosis. Ann Neurol. 1994;36:S15-17.
35. Maciel LM, Rodrigues SS, Dibbern RS, Navarro PA, Donadi EA. Association of the HLA-DRB1 0301 and HLA-DQA1 0501 alleles with Graves? disease in a population representing the gene contribution from several ethnic backgrounds. Thyroid. 2001;11:31-35.
36. Jacobson EM, Huber AK, Akeno N, et al. A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: The role of CD40 tissue-specific expression. Genes Immun. 2007;8:205-214.
37. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and. Nat Genet. 2009;41:824-828.
38. Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1 1501 is regulated by vitamin D. PLoS Genet. 2009;5:e1000369.
39. Ban Y, Ban Y, Taniyama M, Katagiri T. Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves? disease. Thyroid. 2000;10:475-480.
40. Brand OJ, Lowe CE, Heward JM, et al. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves? disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf). 2007;66:508-512.
41. Hafler DA, Compston A, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Eng J Med. 2007;357:851-862.
42. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119:2052-61.
43. International Multiple Sclerosis Genetics Consortium Wellcome Trust Case Control Consortium.
44. Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476:214-219.
45. Weetman AP. Graves? disease. N Engl J Med. 2000;343: 1236-1248.
46. McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid. 2013;23:14-24.
47. Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB. Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review. Eur J Endocrinol. 2012;167:1-5.
48. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28-39.
49. Barbesino G. Drugs affecting thyroid function. Thyroid. 2010;20:763-770.